Market Overview The pulmonary arterial hypertension market is driving as rare disease focus drives orphan drug development incentive across regulatory exclusivity and market exclusivity. The Pulmonary Arterial Hypertension Market is projected to grow through 2035, driven by FDA orphan designation, EMA orphan status, and pediatric investigation plan supporting improved drug development and...